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Abstract
Background: Genes coding for the fatty acid desaturases (FADS1, 2, 3) localized at the cancer genomic hotspot 11q13 locus
are required for the biosynthesis of 20 carbon polyunsaturated fatty acids (PUFA) that are direct eicosanoid precursors. In
several cancer cell lines, FADS2 encoded D6 and D8 desaturation is not functional.
Methodology/Principal Findings: Analyzing MCF7 cell fatty acids with detailed structural mass spectrometry, we show that
in the absence of FADS2 activity, the FADS1 product D5-desaturase operates to produce 5,11,14–20:3 and 5,11,14,17–20:4.
These PUFA are missing the 8–9 double bond of the eicosanoid signaling precursors arachidonic acid (5,8,11,14–20:4) and
eicosapentaenoic acid (5,8,11,14,17–20:5). Heterologous expression of FADS2 restores D6 and D8-desaturase activity and
normal eicosanoid precursor synthesis.
Conclusions/Significance: The loss of FADS2-encoded activities in cancer cells shuts down normal PUFA biosynthesis,
deleting the endogenous supply of eicosanoid and downstream docosanoid precursors, and replacing them with unusual
butylene-interrupted fatty acids. If recapitulated in vivo, the normal eicosanoid and docosanoid cell signaling milieu would
be depleted and altered due to reduction and substitution of normal substrates with unusual substrates, with unpredictable
consequences for cellular communication.
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Introduction
Several human cytogenetic and fine mapping studies have pin-
pointed HSA 11q13 locus as a major hotspot for a number of
human cancers [1,2,3,4,5]. Numerous genetic mechanisms have
been reported, including 11q13 deletions, loss of heterozygosity,
translocations and allelic amplification [3,5]. The fatty acid
desaturase cluster (FADS), encoded by genes FADS1, FADS2,
and FADS3, localize within a 100 kb region on human
chromosome 11q12–13.1 [6,7]. FADS2 and FADS1 encode for
critical enzymes for long chain polyunsaturated fatty acid
(LCPUFA) biosynthesis, introducing double bonds between
specific carbon atoms. Omega-3 (v3o rn 23) and omega-6 (v6
or n26) PUFA are key nutrients linked to most of the diseases of
humans, specifically cardiovascular (CVD), cancer, diabetes and
metabolic syndrome, and are key structural components of neural
tissue [8,9]. The LCPUFA DGLA (20:3n26), ARA (20:4n26),
EPA (20:5n23) and DHA (22:6n23) are precursors for cell
signaling eicosanoids and their modification by biosynthetic
inhibition of downstream metabolism are very valuable drug
targets, for instance, cyclooxygenase and lipoxygenase inhibitors,
and more recently docosanoids that are candidate drugs [10].
The FADS2 encoded D6-desaturase catalyzes the first and rate-
limiting step in the biosynthesis of LCPUFA. In several cancer
cells desaturation does not occur, which may be due to
inactivation of the desaturase or of upstream (e.g. CoA production)
or downstream (e.g. acyl transferase) steps. The reason for this
defect has been suggested to be due to extensive chromosomal
deletions, but no molecular evidence is available [11,12]. The D8-
desaturation substrates 20:2n26 and 20:3n23 are often detected,
thus suggesting that the elongation step is functional [12,13]. Until
recently, the D8-desaturation substrates 20:2n26 and 20:3n23
were widely considered dead-end products, even though they are
found in human plasma and red cells as well as other tissues. We
showed the first molecular evidence that FADS2 catalyzes D8-
desaturation for both of these substrates, representing an
alternative route to LCPUFA biosynthesis in mammals where
they are converted to eicosanoid precursor LCPUFA [14]. This
pathway may be available when D6-desaturase activity is
compromised.
The unusual loss of PUFA desaturase activity in several cancer
cells prompted us to hypothesize that the primary defect resides
in the desaturase itself, and not elsewhere such as in the
activation of PUFA by CoA synthesis or synthesis of phospho-
glycerides as acceptors of nascent LCPUFA. We confirmed that
human breast cancer MCF7 cells do not possess any capacity for
biosynthesis of LCPUFA because of absence of D6-desaturase
activity [12]. Here we show the restoration of this metabolic
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substrate specificity for FADS1, and competition between
FADS1 and FADS2 for the same substrates, leading to the
production of unusual LCPUFA which are not substrates for
eicosanoid production.
Results and Discussion
FADS2 and FADS1 transiently transfected MCF7 cells were
probed for evidence of bioactivity toward 18:2n26 and 18:3n23.
FADS2 transfected cells showed activity towards both the
substrates; gas chromatography-covalent adduct chemical ioniza-
tion tandem mass spectrometry (GC-CACI-MS/MS) confirmed
the new peaks to be 18:3n26 and 18:4n23 respectively (Figure 1).
As expected, no products were observed when either 18:2n26o r
18:3n23 were incubated with the FADS1 and the empty vector
controls. These data provide the first unambiguous molecular
evidence that the metabolic defect in these cells can be restored by
replacing the rate limiting D6-desaturase enzyme encoded by
FADS2.
When FADS1-transfected cells were incubated with 20:2n26
and 20:3n23, CACI-MS/MS shows gain of synthetic function to
generate two new butylene-interrupted PUFA peaks: 5,11,14–20:3
and 5,11,14,17–20:4, respectively (Figure 2). These two LCPUFA
are analogues to arachidonic acid (5,8,11,14–20;4) and eicosa-
pentaenoic acid (5,8,11,14,17–20:5), respectively. Our data
demonstrate that in the substantial absence of D8-desaturase
activity (FADS2), the D5-desaturase (FADS1) operates on
20:2n26 and 20:3n23. D6-desaturation (FADS2) is normally
about 10-fold more active than D5-desaturation (FADS1), thus it is
plausible that during cell transformation FADS1 activity would
persist when FADS2 is inactive. However, the preferred substrates
for FADS1 are not essential fatty acids (18:2n26 and 18:3n23),
but their elongation products 20:2n26 and 20:3n23. FADS1
acting on these substrates generates unusual butylene-interrupted
carbon products and our results show that these rare fatty acids
may be produced in cancer cells. This is the first molecular
evidence showing novel FADS1 substrate specificity for 20:2n26
and 20:3n23 fatty acids. Moreover, FADS2-transfected cells
demonstrate conclusively that the FADS2 gene product D8-
desaturates 20:2n26 and 20:3n23 to 20:3n26 (DGLA) and
20:4n23 (ETA) respectively, equivalent to our results in
heterologously transformed yeast [14].
Moreover, while it is well known that both n23 and n26 PUFA
substrates compete for same enzymes, our current data show
FADS1 and FADS2 competing for the same substrates (Figure 2).
The net consequence is the substitution of the inactive 5,11,14–
20:3 and 5,11,14,17–20:4 for ARA (5,8,11,14–20:4) and EPA
(5,8,11,14,17–20;5), respectively, with unpredictable consequences
for eicosanoid-mediated cell-cell paracrine signaling. Dysregula-
tion of eicosanoid signaling is linked to tumor development,
angiogenesis and metastasis in animal models [15]. A double bond
at position 8 is required for cyclooxygenase (COX), lipoxygenase
(LOX) and thromboxane biosynthesis, and thus the absence of the
double bond at position 8 renders 5,11,14–20:3 and 5,11,14,17–
20:4 inactive as substrates for biosynthesis of most eicosanoids
[16,17,18]. Moreover, the possible action of the butylene-
interrupted PUFA as competitive inhibitors of eicosanoid
biosynthetic enzymes is unknown, as is the activity of other key
eicosanoid synthetic enzymes (e.g. cytochrome P450) whose
actions on normal parts of the unusual fatty acids would result
in products with unknown activit(ies).
FADS genes, encoding enzymes required for PUFA biosynthesis
arose evolutionarily by gene duplication events. Despite key
importance of FADS2 and the loss of its function in several cancer
cells, the molecular details and consequences of FADS2 loss has
not been described or investigated. FADS2 is known to have
activity towards at least seven substrates (18:2n26, 18:3n23,
20:2n26, 20:3n23, 24:4n26, 24:5n23, 16:0). The loss of
FADS2-encoded activities in cancer cells completely shuts down
the classical and alternative PUFA pathways, eliminating eicosa-
noid and docosanoid precursor biosynthesis from the plant-based
PUFA linoleic and linolenic acids and thus limiting cell-cell
signaling (Figure 3). Many studies have found strong associations
between single nucleotide polymorphisms within the FADS gene
cluster and complex phenotypes related to chronic disease, as well
Figure 1. GC results of transfected MCF7 cells with18:2n-6 and18:3n-3 fatty acids. A: No product is seen in FADS1-transfected cells.
B: FADS2 transfected cells D6-desaturate 18:2n26R18:3n26 (9,12–18:2 R 6,9,12–18:2) and 18:3n–3R18:4n23 (9,12,15–18:3 R 6,9,12,15–18:4).
doi:10.1371/journal.pone.0028186.g001
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to fully understand the consequences of FADS gene function loss
and/or modulation based on SNPs in neoplasm. Early studies
demonstrated that micro-cell mediated transfer of HSA11 into
MCF7 cells reduced tumorigenicity, suggestive of potential tumor
suppressor genes on this chromosome [21].
Our findings show that a primary molecular defect in MCF7
cells lies within the FADS2 gene causing loss of FADS2-encoded
D6-desaturase activity. Compensation for FADS2 function by
FADS1 leads to the production of 5,11,14–20:3 and 5,11,14,17–
20:4, both primarily dead-end fatty acid products that cannot be
precursors for most eicosanoids and are likely to be competitive
Figure 2. GC results of FADS2 transfected MCF7 cells with 20:2n26 (8,11–20:2) and 20:3n23 (8,11,14–20:3) fatty acids. A: FADS1-
transfected cells D5-desaturate 20:2n26R5,11,14–20:3 and 20:3n23R5,11,14,17–20:4. B: FADS2 transfected cells D8-desaturate 20:2n26R20:3n26
and 20:3n23R20:4n23.
doi:10.1371/journal.pone.0028186.g002
Figure 3. n26 LCPUFA pathway in MCF7 cells. D6- and D8-desaturation steps are absent in MCF7, leading to D5-desaturation of 11,14–20:2 to
5,11,14–20:3 when FADS1 is functional. The analogous pathways for n–3 LCPUFA convert 11,14,17–20:3R5,11,14,17–20:4 (not shown). FADS2 is also
believed to be involved in C22 LCPUFA biosynthesis (not shown).
doi:10.1371/journal.pone.0028186.g003
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PUFA in cancer cells calls for further detailed investigation. Our
present results provide an impetus to better understanding the role
of fatty acid desaturases, especially FADS2 as a tumor suppressor
in neoplastic disorders.
Materials and Methods
Plasmid vector construction
The protein coding sequences of FADS1 (GenBank Accession#
EF531577) and FADS2 (GenBank Accession# EU780003) were
cloned into pcDNA3.1 expression vector using cDNA from
neonate baboon liver tissue. The cDNA was obtained from
banked samples drawn from a study approved by the Cornell
University Institutional Animal Care and Use Committee
(IACUC, protocol # 02–105). Analysis and comparison of amino
acid sequence of baboon FADS1 showed 95% identities and 97%
positives with human FADS1 (AF084558), whereas, baboon
FADS2 showed 98% identities and 99% positives with human
FADS2 (NM_004265). Earlier, we have shown novel D8-
desaturation function using baboon FADS2 [14].
MCF7 cell culture and fatty acid supplementation
For transfection experiments MCF7 cells were grown in MEM-
a media with 10% Lipid-reduced FBS (media and serum obtained
from HyClone) at 37uC in a humidified environment with 5%
CO2. Human breast cancer MCF7 cells (American Type Culture
Collection, ATCC, Rockville, MD) were the kind gift of Dr. Rui
Hai Liu, Cornell University. The FADS1 and FADS2 constructs
were transfected into MCF7 cells using Lipofectamine LTX
(Invitrogen, USA) as per the manufacturer’s recommendations.
Twenty four hours after transfection, the MCF7 cells were
supplemented with 100 mM of albumin bound 18:2n26,
18:3n23, 20:2n26 and 20:3n23 fatty acids and were incubated
for additional 24 hours.
Fatty acid analysis
After incubation with fatty acids, the cells were washed twice
with 1XPBS and removed by trypsinization. The cells were
harvested by centrifugation and the cell pellet was processed for
lipid extraction. Fatty acid methyl ester preparation was carried
out using a modified one-step method of Garces and Mancha [22].
Analysis was by gas chromatography-flame ionization detection
(GC-FID) [8] and peak identification was confirmed by GC-
covalent adduct chemical ionization tandem mass spectrometry
(GC-CACI-MS/MS) [14,23].
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